Dr
Haider
Al-Janabi
School of Medicine and Population Health
Postdoctoral Research Associate
h.h.al-janabi@sheffield.ac.uk
+44 114 215 9209
+44 114 215 9209
The Medical School
Full contact details
Dr Haider Al-Janabi
The Medical School
School of Medicine and Population Health
The Medical School
Beech Hill Road
Sheffield
S10 2RX
- Publications
-
Journal articles
- Targeting a STING agonist to perivascular macrophages in prostate tumors delays resistance to androgen deprivation therapy. Journal for ImmunoTherapy of Cancer, 12(7). View this article in WRRO
- Nanobugs as drugs: bacterial derived nanomagnets enhance tumor targeting and oncolytic activity of HSV‐1 virus. Small, 18(13). View this article in WRRO
- Macrophage Regulation of the Development of Castration-Resistant Prostate Cancer. Cancer Research, 81(21), 5399-5400.
- Macrophages Mediate the Anti-Tumor Effects of the Oncolytic Virus HSV1716 in Mammary Tumors.. Mol Cancer Ther.
- Magnetic-silk/polyethyleneimine core-shell nanoparticles for targeted gene delivery into human breast cancer cells. International Journal of Pharmaceutics, 555, 322-336. View this article in WRRO
Conference proceedings
- Abstract LB-188: Breast cancer immunotherapy using magnetized HSV1716. Cancer Research, Vol. 79(13_Supplement)
- Abstract LB-136: Targeting perivascular macrophages to prevent castration resistance in men with high-risk, localized prostate cancer. Cancer Research, Vol. 79(13_Supplement)
Other
- Data from Macrophages Mediate the Antitumor Effects of the Oncolytic Virus HSV1716 in Mammary Tumors.
- Data from Macrophages Mediate the Antitumor Effects of the Oncolytic Virus HSV1716 in Mammary Tumors.
- Supplementary Data from Macrophages Mediate the Antitumor Effects of the Oncolytic Virus HSV1716 in Mammary Tumors.
- Supplementary Data from Macrophages Mediate the Antitumor Effects of the Oncolytic Virus HSV1716 in Mammary Tumors.
- Targeting a STING agonist to perivascular macrophages in prostate tumors delays resistance to androgen deprivation therapy. Journal for ImmunoTherapy of Cancer, 12(7). View this article in WRRO